Rocket Pharmaceu Stock Price, News & Analysis

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that CEO Gaurav Shah will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, Sept. 13, at 3:30 p.m. ET. A live audio webcast will be available on the company’s Investors section of their website. Rocket focuses on developing genetic therapies for rare childhood disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency. For more information, visit www.rocketpharma.com.

Rocket Pharmaceuticals (NASDAQ: RCKT) reported positive safety data from its Phase 1 Danon Disease study, indicating RP-A501 was well-tolerated in pediatric patients. They announced 100% overall survival in a pivotal Phase 2 trial for severe LAD-I, with regulatory filings expected in early 2023. The primary endpoint for the Fanconi Anemia trial was met, initiating FDA dialogue for BLA planning. The company reported a cash position of $321.4 million, ensuring operational runway into H1 2024. The appointment of Mayo Pujols as Chief Technical Officer bolsters its leadership in gene therapy.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has appointed Mayo Pujols as Chief Technical Officer and Executive Vice President. Pujols, with nearly 30 years of experience in technical operations and gene therapy, previously served as CEO of Andelyn Biosciences. He will oversee Rocket's cGMP-ready AAV manufacturing facility in Cranbury, N.J., preparing for a Phase 2 pivotal trial for Danon Disease. His leadership aims to enhance the company’s gene therapy capabilities and advance regulatory filings for its lentiviral platform.

Rocket Pharmaceuticals (NASDAQ: RCKT), a leader in genetic therapies for childhood disorders, announces CEO Gaurav Shah's participation in the William Blair Biotech Focus Conference on July 12-13, 2022, in New York City. A pre-recorded fireside chat will be accessible starting July 11 at 9:00 a.m. ET. The discussion will focus on Rocket's innovative gene therapy pipeline, including recent positive trial data for severe Leukocyte Adhesion Deficiency-I and updates on Fanconi Anemia and other conditions. More details can be found on Rocket's investor website.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported positive results from its Phase 2 trial for RP-L201, a gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). The trial demonstrated 100% overall survival at one year post-infusion and significant clinical improvement in patients. All nine patients showed sustained CD18 expression with no serious adverse events. Rocket plans to engage health authorities for regulatory filings anticipated in the first half of 2023, focusing on the therapy's potential to transform treatment options for LAD-I.

Rocket Pharmaceuticals (NASDAQ: RCKT) recently announced promising clinical updates from its ongoing gene therapy trials. The Phase 1 trial for RP-A501 in Danon Disease showed the treatment was well-tolerated in pediatric patients with no reported toxicities. In the Phase 2 trial for Fanconi Anemia, five out of nine patients exhibited sustained increased resistance to mitomycin-C, achieving the trial's primary endpoint. Additionally, treatments for Pyruvate Kinase Deficiency demonstrated normalized hemoglobin levels in patients 18 months post-infusion.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is set to present at the UBS Global Healthcare Conference on May 24 at 7:45 a.m. ET in New York. CEO Gaurav Shah will deliver the presentation, with a live audio webcast available on the company's website. Rocket focuses on developing genetic therapies for rare childhood disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency. The company employs a platform-agnostic approach to offer innovative treatment options, addressing significant unmet needs in pediatric healthcare.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported a net loss of $43M, or $0.67 per share, for Q1 2022. The company holds $346.6M in cash, extending its operational runway into H1 2024. Key updates include the advancement of four clinical programs targeting Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency, with data readouts expected throughout 2022. Significant leadership appointments were made, including Fady Malik, M.D., to the Board and Carlos Martin as Chief Commercial Officer. The company also anticipates AAV cGMP manufacturing readiness in Q2 2022.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is set to present at the Bank of America Securities Healthcare Conference on May 11 at 2:20 p.m. ET. The company specializes in developing genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease. Rocket utilizes a platform-agnostic approach, focusing on tailored therapy solutions. Given the ongoing impact of COVID-19, the company emphasizes the safety and effectiveness of its product candidates, while also addressing potential delays in clinical trials.